Advertisement
"With the launch of the named-patient/compassionate use program, Gentareaffirms its commitment to make Genasense available to patients in need whilewe are conducting additional registration-quality clinical trials," said Dr.Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Withpublished results earlier this year of our randomized trials in melanoma andchronic lymphocytic leukemia, the Company has received a number of requestsfor Genasense to treat specific patients. We are pleased to make this programavailable to patients outside the U.S. We expect that proceeds from this newprogram will be used to offset costs associated with our confirmatoryrandomized trial in patients with advanced melanoma."
Advertisement
About Genta
Genta Incorporated is a biopharmaceutical company with a diversifiedproduct portfolio that is focused on delivering innovative products for thetreatment of patients with cancer. The Company's research platform isanchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium)Injection is the Company's lead compound from its oligonucleotide program.The leading drug in Genta's small molecule program is Ganite(R) (galliumnitrate injection), which the Company is exclusively marketing in the U.S. fortreatment of symptomatic patients with cancer related hypercalcemia that isresistant to hydration. Genta is partnered with IDIS (www.idispharma.com) ona program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more informationabout Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect tobusiness conducted by Genta Incorporated. By their nature, forward-lookingstatements and forecasts involve risks and uncertainties because they relateto events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:
The Company does not undertake to update any forward-looking statements.There are a number of factors that could cause actual results and developmentsto differ materially. For a discussion of those risks and uncertainties,please see the Company's Annual Report on Form 10-K for 2006 and its mostrecent quarterly report on Form 10-Q.-- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA"); -- the safety and efficacy of the Company's products or product candidates; -- the Company's assessment of its clinical trials; -- the commencement and completion of clinical trials; -- the Company's ability to develop, manufacture, license and sell its products or product candidates; -- the Company's ability to enter into and successfully execute license and collaborative agreements, if any; -- the adequacy of the Comp
